Michael Kramer, MD, PhD

Medical School Department Internal Medicine
Research Program Hematopoietic Development & Malignancy
Michael Kramer

Researcher Background

Primary Academic Title

Instructor, Department of Internal Medicine, WashU Medicine

Training

  • 2018 - 2020: Resident, Internal Medicine, Barnes-Jewish Hospital, WashU Medicine, St. Louis, MO
  • 2020 - 2024: Fellow, Hematology and Oncology, Barnes-Jewish Hospital, WashU Medicine, St. Louis, MO

Education

  • 2009: BA, Harvard College, Cambridge, MA
  • 2016: PhD, University of California, San Diego, CA
  • 2018: MD, University of California, San Diego, CA

Research & Selected Publications

Research Interest

Dr. Kramer is a physician-scientist studying blood cancers, particularly acute myeloid leukemia (AML). He published a proteomic and phosphoproteomic study of AML that identified examples of posttranscriptionally regulated proteins in patients with recurrent AML driver mutations, and identified cell surface proteins that may be targets for immunologic therapies. He is utilizing protein-protein interaction screening to identify protein interactions with oncogenic driver proteins that can be targeted therapeutically, and is utilizing machine learning to predict and design molecules that interact with oncogenic driver proteins. Clinically, Dr. Kramer sees patients with blood cancers on the inpatient Hematologic Malignancies service.

Research Publications

Overexpression of the signaling coordinator GAB2 can play an important role in acute myeloid leukemia progression.
Authors:

Kramer MH, Richardson SN, Li Y, one or more additional authors omitted Ley TJ

Journal & Year:

J Clin Invest • 2025

Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk.
Authors:

Tran D, Beeler JS, Liu J, one or more additional authors omitted Kramer MH, one or more additional authors omitted Bolton KL

Journal & Year:

Clin Cancer Res • 2024